Linguistic Validation of the Rett Syndrome Behavior Questionnaire Spanish Translation: a Two-Stage Caregiver Study Across Latin America

This study successfully developed and validated a culturally and linguistically equivalent Spanish translation of the Rett Syndrome Behavior Questionnaire through a two-stage caregiver study across Latin America, demonstrating high comprehension, strong test-retest reliability, and feasibility for broader inclusion of Spanish-speaking populations in Rett syndrome research and clinical trials.

The Gist

Imagine you have a very specific, detailed map for navigating a complex city. This map, called the Rett Syndrome Behavior Questionnaire (RSBQ), has been the gold standard for doctors and researchers for decades. It helps them understand exactly what a child with Rett Syndrome is experiencing, from their mood to their breathing and hand movements.

However, there's a big problem: this map only exists in British English.

For families in Latin America who speak Spanish, trying to use this map is like trying to navigate a city in Tokyo using a guidebook written only in English. You might get the general idea, but you'll miss the nuances, get lost in translation, and feel left out of the journey.

This paper is the story of how a team of researchers and caregivers built a brand new, high-quality Spanish version of this map specifically for families in Latin America.

Here is the story of how they did it, broken down into simple steps:

1. The Problem: A Language Barrier in a Medical World

Rett Syndrome is a rare condition that mostly affects girls. Because it's rare, every bit of data counts. But for years, if a family in Mexico, Argentina, or Peru wanted to join a clinical trial or get their child's symptoms measured accurately, they hit a wall. They had to guess how to answer English questions, or use rough, unofficial translations that didn't quite capture the meaning.

The Analogy: Imagine trying to describe the taste of a specific fruit to someone who has never eaten it, but you can only use words from a language they don't speak. You might say "sweet," but they might think you mean "sour." The data becomes unreliable, and the families are excluded from the conversation.

2. The Mission: Building a Bridge, Not Just a Translation

The team didn't just want to translate words; they wanted to translate meaning. They knew that a word like "miserable" in English might feel too heavy or dramatic in some Spanish dialects, or that a phrase about "hand movements" might sound confusing if not phrased just right.

The Analogy: They weren't just swapping Lego bricks from one color to another; they were rebuilding the whole structure so it fit perfectly in a new house.

3. The Process: Two Stages of Testing

To make sure the new Spanish map was perfect, they used a two-step "test drive" with real families.

• Phase 1: The Guided Tour (The "Cognitive Debriefing")
  The researchers sat down (virtually) with 12 caregivers. They read the questions out loud, one by one, and asked, "Does this make sense to you? How would you say this in your own words?"

  • What happened: They found that some words were confusing. For example, the word "miserable" was changed to "sad or downcast" because "miserable" sounded too extreme in some regions. They realized that for questions about walking, they needed to add "if applicable" because many children with Rett Syndrome cannot walk yet.
  • The Result: They polished the language until it felt natural to a native speaker, not like a robot translation.

• Phase 2: The Test Drive (Reliability Check)
  Once the language was polished, they sent the new questionnaire to 51 families across Latin America (from Argentina to Guatemala). These families filled out the survey, waited a week or two, and then filled it out again.

  • The Goal: If the map is accurate, the answers should be very similar the second time (unless the child's condition actually changed).
  • The Result: The answers were almost identical! This proved that the new Spanish version was reliable. It measured the same things as the English version, just in a language everyone could understand.

4. The Outcome: A New Era for Latin America

The study was a huge success. It showed that:

• Families are ready: When given the right tools, families in Latin America are eager to participate in research.
• The tool works: The Spanish questionnaire is just as accurate as the English one.
• The future is brighter: Now, doctors in Spanish-speaking countries can use this tool to diagnose children faster and more accurately. It also means families in Latin America can finally join international clinical trials for new drugs, ensuring they aren't left behind in medical breakthroughs.

The Big Picture

Think of this study as unlocking a door. For a long time, the door to high-quality medical research for Rett Syndrome was locked for Spanish speakers. This paper provides the key.

By validating this Spanish questionnaire, the researchers haven't just translated a list of questions; they have translated hope. They have ensured that a mother in Peru or a father in Mexico can speak up for their child with the same clarity and precision as anyone else in the world, paving the way for better treatments and a brighter future for all children with Rett Syndrome.

Technical Summary

1. Problem Statement

Rett Syndrome (RTT) is a severe neurodevelopmental disorder affecting approximately 1 in 10,000 female births. The Rett Syndrome Behaviour Questionnaire (RSBQ) is the gold-standard, FDA-accepted instrument for assessing RTT behavioral phenotypes and is a primary efficacy endpoint in clinical trials (e.g., for trofinetide). However, the RSBQ was originally validated only in British English.

This lack of a validated Spanish version creates significant barriers:

• Clinical Exclusion: Spanish-speaking caregivers and clinicians in Latin America and Spain cannot systematically track symptoms or participate in international trials using standardized metrics.
• Diagnostic Delays: RTT is often underdiagnosed in Latin America due to limited access to genetic testing and a lack of culturally adapted assessment tools, leading to misclassification as autism or cerebral palsy.
• Data Gap: As RTT diagnoses rise in Latin America due to improved genetic awareness, there is an urgent need for a linguistically and culturally equivalent instrument to facilitate research and therapeutic development in the region.

2. Methodology

The study employed a rigorous, two-phase linguistic validation process involving Spanish-speaking caregivers across Latin America, conducted between November 2023 and September 2025.

Phase 0: Translation and Clinical Review

• The original English RSBQ was translated into Spanish by a certified medical translator in Colombia.
• A back-translation was performed by a bilingual clinician.
• A pediatric neurologist (native Spanish speaker, fluent English) reviewed both versions for clinical accuracy.

Phase I: Guided Administration and Cognitive Debriefing

• Participants: 12 native Spanish-speaking RTT caregivers recruited via advocacy networks.
• Process: One-on-one virtual sessions where an investigator read items aloud. Caregivers could ask for clarifications and suggest linguistic modifications.
• Goal: To identify items with low comprehension, cultural mismatches, or ambiguous wording (cognitive debriefing).
• Outcome: Consensus-based modifications were made to specific questions based on caregiver feedback and clinician review.

Phase II: Test-Retest Reliability Study

• Participants: 134 initial submissions from caregivers across Latin America (Argentina, Mexico, Peru, Colombia, Uruguay, Guatemala, and US-based Spanish speakers).
• Data Cleaning: 15 duplicate entries were removed, resulting in a final dataset of 51 unique caregivers who completed both the initial survey and a retest.
• Timeline: Participants completed the survey, and a retest was administered automatically after a minimum of 7 days. The mean interval was 45.4 days (median 11 days), with a bimodal distribution (7–8 days and 80–100 days).
• Statistical Analysis:
  • Reliability: Intraclass Correlation Coefficient (ICC) using a 2-way mixed-effects model (absolute agreement).
  • Agreement: Bland-Altman plots to assess bias and limits of agreement.
  • Sub-analysis: Data was stratified by time interval (<21 days vs. >21 days) to control for disease progression confounding long-interval retests.

3. Key Contributions

• First Validated Spanish RSBQ: This study produced the first formally linguistically validated Spanish version of the RSBQ, specifically adapted for Latin American dialects and cultural contexts.
• Refined Instrument: The study identified and corrected 7 critical items where the initial translation caused confusion (e.g., the word "miserable" was changed to "cabizbaja o triste" to avoid regional negative connotations; "uniforme/monótono" was changed to "invariable y repetitivo").
• Methodological Model: Demonstrated a feasible, collaborative model for validating clinical instruments in rare disease populations across geographically dispersed regions using virtual engagement and patient advocacy networks.

4. Key Results

• Demographics: The 51 participants represented 7 countries, with the majority from Argentina (39.2%), Mexico (31.4%), and Peru (11.8%). 92% were female caregivers.
• Comprehension: The guided Phase I sessions successfully identified linguistic nuances, resulting in a final questionnaire with high caregiver comprehension and engagement.
• Reliability (Test-Retest):
  • Overall ICC: The Intraclass Correlation Coefficient for the total score was 0.907 (95% CI: 0.843–0.946), indicating excellent reliability.
  • Agreement: 92.2% (47/51) of paired responses fell within 2 standard deviations on the Bland-Altman plot.
  • Time Interval Effect: A slight correlation was observed between longer retest intervals (>80 days) and score variability, attributed to natural disease progression rather than instrument instability.
  • Short-Interval Analysis: When restricting analysis to participants with <21-day intervals (n=31), the ICC remained robust, and no specific question showed significant intra-rater variability (Kruskal-Wallis p = 0.7392).
• No Bias: No questions showed biased response distributions, confirming the cultural neutrality of the adapted items.

5. Significance and Implications

• Clinical Equity: The validated Spanish RSBQ removes language barriers, allowing Spanish-speaking families to participate in global clinical trials and enabling clinicians in Latin America to standardize behavioral assessments.
• Research Readiness: The instrument is now ready for use in multinational therapeutic trials, facilitating the inclusion of Latin American cohorts in global datasets and regulatory submissions (e.g., FDA/EMA).
• Healthcare System Integration: The study highlights a mobilized caregiver community and advocacy infrastructure in Latin America. Hospitals and clinical centers have already expressed interest in integrating the Spanish RSBQ into diagnostic pathways to reduce diagnostic delays.
• Future Directions: While the current study covers major Latin American nations, future work aims to expand validation to Spain, the Caribbean, and other underrepresented Spanish-speaking populations to ensure broader dialectal neutrality.

Conclusion:
This study successfully bridges a critical gap in rare disease research by providing a culturally and linguistically validated tool for Rett Syndrome in the Spanish-speaking world. It empowers caregivers, standardizes clinical data collection, and lays the groundwork for equitable therapeutic development in Latin America.